Prostate Cancer

Alicia Morgan, MD, Mather Hospital, discusses the role of PARP inhibitors for patients with prostate cancer.

William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of medicine and urology, Mount Sinai Hospital, discusses the role of immunotherapy for patients with prostate cancer.

Layering of therapies and advances in next-generation imaging and sequencing are key reasons that outcomes are improving in advanced prostate cancer.

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses the advantages and disadvantages of choosing docetaxel as a therapy for patients with mCRPC.

For patients with oligorecurrent prostate cancer, androgen deprivation therapy–free survival was superior for those assigned to metastasis-directed therapy versus surveillance.

One-third of asymptomatic men with metastatic castration-resistant prostate cancer who progressed on enzalutamide (Xtandi) achieved a 50% decline in PSA concentration from baseline (PSA50) following bipolar androgen therapy.

Christopher Sweeney, MBBS, medical oncologist, Dana-Farber Cancer Institute, discusses tailoring treatment to individual patients with prostate cancer.

Although gene fusions between the TMPRSS2 gene and ETS family of transcription factors in prostate cancer have been recognized for more than a decade, the clinical relevance of this fusion event continues to be debated among experts.

Julie Graff, MD, assistant professor of medicine, OHSU Knight Cancer Institute, discusses the treatment of prostate cancer.

William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of medicine and urology, Mount Sinai Hospital, discusses the hormone-sensitive setting of prostate cancer.

Men with metastatic castration-resistant prostate cancer who progressed following initial treatment with an androgen receptor-axis-targeted agent had better survival when treated with docetaxel in second-line.

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses androgen receptor (AR) inhibitors for patients with prostate cancer.

Julie Graff, MD, assistant professor of medicine, OHSU Knight Cancer Institute, discusses the role of checkpoint inhibitors and PARP inhibitors for patients with prostate cancer.

Alicia Morgan, MD, discusses the role of PARP inhibitors as a novel treatment strategy for patients with metastatic castration-resistant prostate cancer.

The FDA has granted a priority review to a new drug application for apalutamide for the treatment of patients with nonmetastatic castration-resistant prostate cancer.

Alicia Morgan, MD, Mather Hospital, discusses the role of olaparib (Lynparza) for patients with metastatic castration-resistant prostate cancer (mCRPC).

Julie Graff, MD, comments on the state of immunotherapy in mCRPC and some ongoing research in the field.

William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of medicine and urology, Mount Sinai School of Medicine, discusses the use of abiraterone acetate (Zytiga) and docetaxel (Taxotere) in patients with metastatic castration-resistant prostate cancer.

William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of medicine and urology, Mount Sinai School of Medicine, explains when he would choose abiraterone acetate (Zytiga) for patients with prostate cancer.

Three-year safety results from the ALSYMPCA trial showed that treatment with radium-223 dichloride (Xofigo) for men with mCRPC and symptomatic bone metastases was associated with minimal nonhematologic AEs.